This study investigated the effects of the peroxisome proliferator-activated receptor-g agonist rosiglitazone (RGZ) on cardiac fibroblast proliferation, nitric oxide content and connective tissue growth factor (CTGF) expression following incubation with advanced glycation endproducts (AGEs). Cultured neonatal rat cardiac fibroblasts were incubated with various concentrations of AGEs for 48 h. Cells were also incubated with 200 mg/l AGEs plus various concentrations of RGZ. Cardiac fibroblast proliferation and cell cycle status were detected using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and flow cytometry. Western blotting was used to measure the expression of CTGF and nitric oxide content was evaluated using a nitrate reductase assay. AGEs significantly accelerated proliferation, increased CTGF expression and decreased nitric oxide production in cardiac fibroblasts. These effects of AGEs were inhibited by RGZ in a dose-dependent manner. Treatment with RGZ could be a valuable therapeutic approach in diabetic patients with myocardial fibrosis.
Introduction
Advanced glycation end-products (AGEs) have been proposed as toxic mediators of diabetic complications and ageing. 1 Myocardial fibrosis and myocyte hypertrophy are characteristic changes seen in diabetic cardiomyopathy. Cytokines such as connective tissue growth factor (CTGF) and transforming growth factor-β (TGF-β) 2 are overexpressed in diabetic myocardium and may be involved in the pathogenesis of diabetic cardiomyopathy. CTGF belongs to the family of immediate early proteins known as CCN (acronym for CTGF, Cysteinrich protein and Nephroblastoma overexpressed gene) and is involved in cell J Li, NF Liu, Q Wei Effects of rosiglitazone proliferation, migration and matrix production.
Peroxisome proliferator-activated receptor-γ (PPAR-γ) is a nuclear hormone transcription factor that regulates genes associated with lipid and glucose metabolism. Activation of PPAR-γ also inhibits pro-inflammatory pathways, including cytokine secretion and inducible nitric oxide synthase (iNOS) expression, in a variety of cell lines. 3, 4 It is not known, however, whether the PPAR-γ agonist rosiglitazone (RGZ) inhibits the effects induced by AGEs. The purpose of this study was to determine the effect of RGZ on changes in cardiac fibroblast proliferation, CTGF expression and nitric oxide production induced by AGEs.
Materials and methods

SYNTHESIS OF AGES
The AGEs were synthesized under sterile conditions by incubating 20 mg/ml bovine serum albumin (BSA, low endotoxin; Merck, Darmstadt, Germany) with 50 mmol/l glucose for 90 days, as previously described, 5 then fully dialysing against phosphatebuffered saline to remove unbound glucose. Incubation of BSA without glucose under the same conditions was used as a negative control.
CELL CULTURE
Primary cardiac fibroblasts were cultured as previously described. 6 Approximately 80% confluent cells after three to four passages were exposed to various concentrations of AGEs (0, 50, 100, 200 or 400 mg/l) or BSA (200 mg/l) for 48 h. A second set of cardiac fibroblasts were pretreated with RGZ (0, 0.1, 1 or 10 µmol/l) for 48 h; these cells were then exposed to AGEs at a dose of 200 mg/l or BSA in the same manner as the control cells. Conditioned serum-free medium was collected for measurement of nitrate and nitrite formation.
WESTERN BLOT
The expression of CTGF protein in the cardiac fibroblasts was analysed by Western blot using rabbit anti-mouse CTGF antibody (Biovision Inc., Mountain View, CA, USA) at a 1:250 dilution, as previously described. 7
CELL PROLIFERATION AND CELL CYCLE ASSAY
Cardiac fibroblast proliferation and cell cycle status were detected using a 3-(4,5dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and flow cytometry as previously described. 7 The results of the MTT assay were measured in terms of absorbance at 490 nm (A 490 ).
MEASUREMENT OF NITRIC OXIDE PRODUCTION
Nitric oxide production in the culture supernatant was assayed by measuring nitrate and nitrite, two metabolites of nitric oxide, using a test kit (Jian Cheng Chemical Co., Nanjing, China).
STATISTICAL ANALYSIS
All data were expressed as means ± SD. Data were evaluated using analysis of variance and, when indicated, subjected to post-hoc comparisons using Dunnett's test (SPSS ® statistical software version 11.5; SPSS Inc., Chicago, IL, USA). A two-tailed P-value < 0.05 was considered to be statistically significant.
Results
CARDIAC FIBROBLAST PROLIFERATION
Exposure of cardiac fibroblasts for 48 h to AGEs at doses of 0 -200 mg/l induced a dose-dependent increase in cell proliferation J Li, NF Liu, Q Wei Effects of rosiglitazone (measured by MTT assay as an increase in A 490 ; Table 1 ), that was significant at 100 (P < 0.05) and 200 mg/l AGEs (P < 0.01) compared with the control (0 mg/l). Proliferation then returned to a level similar to that of the control at 400 mg/l AGEs.
The percentage of cardiac fibroblasts at the S stage of the cell cycle was significantly higher in samples exposed to 50 (P < 0.05), 100 (P < 0.01) and 200 mg/l AGEs (P < 0.01) compared with the control, with a corresponding significant decrease in the proportion of cells in the G 0 /G 1 phase (Table   1) . No difference was seen between the samples exposed to 400 mg/l AGEs compared with the control group.
The effects of 0.1, 1 or 10 µmol/l RGZ on the changes in cardiac fibroblast proliferation are shown in Table 2 . At all concentrations of RGZ the cell proliferation, evaluated based on the A 490 , was significantly reduced compared with the 200 mg/l AGEs group. RGZ also produced a significant dose-dependent increase in the proportion of cells in the G 0 /G 1 phase and a significant decrease in the proportion of cells in the S phase. 
Cell cycle status
AGEs (mg/l) n A 490 G 0 /G 1 (%) S (%) 0 (control) 5 0.622 ± 0.
Effect of rosiglitazone (RGZ) on changes in cardiac fibroplast proliferation, measured using an MTT assay and quantified by absorbance at 490 nm (A 490 ), and cell cycle status in cardiac fibroblasts induced by incubation for 48 h with 200 mg/l advanced glycation endproducts (AGEs)
J Li, NF Liu, Q Wei Effects of rosiglitazone NITRIC OXIDE PRODUCTION AND CTGF EXPRESSION
Exposure of cardiac fibroblasts to AGEs at all doses tested (50, 100, 200, 400 mg/l) inhibited nitrite production in a dosedependent manner. The mean baseline concentration of nitric oxide (calculated from the nitrate and nitrite concentrations) was 37.45 ± 5.7 µmol/l. The nitric oxide concentration decreased significantly compared with baseline after the cardiac fibroblasts were incubated with 100 -400 J Li, NF Liu, Q Wei Effects of rosiglitazone mg/l AGEs (P < 0.01) ( Fig. 1) . Doses of 50 -400 mg/l AGEs also stimulated a significant dose-dependent increase in CTGF expression in cardiac fibroblasts compared with the control and BSA (P < 0.01) (Fig. 2) .
The effects of RGZ on changes in nitric Fig. 3 : the decrease in nitric oxide content was inhibited by RGZ in a dose-dependent manner. Moreover, as shown in Fig. 4 , Western blot indicated that pretreatment with 0.1 -10 µmol/l RGZ dose-dependently inhibited CTGF protein production compared with 200 mg/l AGEs (P < 0.01).
Discussion
The present study demonstrated that AGEs stimulated cardiac fibroblast proliferation in a dose-dependent manner up to 200 mg/l, however there was a decrease in proliferation in cardiac fibroblasts exposed to 400 mg/l AGEs, suggesting toxicity. AGEs also increased CTGF expression in a dose-dependent manner; initial levels of CTGF expression were low in these normal cardiac fibroblasts.
In diabetes, AGEs not only stiffen structural collagen backbones but also act as agonists to AGE receptors (RAGE), which are present on various cell types. RAGE activation stimulates the release of profibrotic growth factors, promotes collagen deposition, increases inflammation and, ultimately, leads to tissue fibrosis. 8 In the present study, pretreatment of cardiac fibroblasts with the PPAR-γ agonist RGZ inhibited the cell proliferation and increased CTGF expression induced by AGEs.
The present study also showed that AGEs decreased nitric oxide production in cardiac fibroblasts in a dose-dependent manner. Besides regulating vascular tone, nitric oxide has a protective effect on endothelial cells and is involved in inhibitory modulation of cardiovascular remodelling. 9 The results of the present study differ from previous studies in which AGEs were found to increase nitrite production and iNOS expression in glomerular mesangial cells. 10 In these cells AGEs appeared to induce iNOS expression through a nuclear factor-κB-dependent pathway, whereas RGZ inhibits AGE-induced iNOS expression via a p38 mitogen activated protein kinase-dependent pathway. 10 -12 In contrast, our results are consistent with a previous report showing the PPAR-γ ligand, ciglitazone, potentiates interleukin-1β/tumour necrosis factor-α-induced iNOS expression three-fold by increasing iNOS mRNA stability. 13 These authors suggested that PPAR-γ agonists amplify iNOS expression while inhibiting nuclear factor-κB in mesangial cells. Recent reports have also demonstrated that RGZ treatment of patients with diabetes reduced NAD(P)H oxidasemediated superoxide production, increases nitric oxide bioavailability in endothelial progenitor cells and restores reendothelialization capacity. 14 These effects may contribute to the vasoprotective actions of RGZ. Our present study suggests that RGZ may be involved in nitric oxide release.
In summary, the present study demonstrated that RGZ inhibits cardiac fibroblast proliferation, increases CTGF expression and decreases nitric oxide production induced by AGEs. This inhibition may involve differing mechanisms related to PPAR-γ activation in various cell types. Treatment with RGZ, which activates PPAR-γ, could be a valuable therapeutic approach in diabetic patients with myocardial fibrosis.
